AU2017247008B2 - Isoflavonoid composition with improved pharmacokinetics - Google Patents

Isoflavonoid composition with improved pharmacokinetics Download PDF

Info

Publication number
AU2017247008B2
AU2017247008B2 AU2017247008A AU2017247008A AU2017247008B2 AU 2017247008 B2 AU2017247008 B2 AU 2017247008B2 AU 2017247008 A AU2017247008 A AU 2017247008A AU 2017247008 A AU2017247008 A AU 2017247008A AU 2017247008 B2 AU2017247008 B2 AU 2017247008B2
Authority
AU
Australia
Prior art keywords
formula
compound
hours
administration
rectal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017247008A
Other languages
English (en)
Other versions
AU2017247008A1 (en
Inventor
Graham Kelly
Kate PORTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noxopharm Ltd
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of AU2017247008A1 publication Critical patent/AU2017247008A1/en
Application granted granted Critical
Publication of AU2017247008B2 publication Critical patent/AU2017247008B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017247008A 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics Ceased AU2017247008B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
AUPCT/AU2016/050674 2016-07-28
US201762480692P 2017-04-03 2017-04-03
US62/480,692 2017-04-03
PCT/AU2017/050301 WO2017173498A1 (en) 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics

Publications (2)

Publication Number Publication Date
AU2017247008A1 AU2017247008A1 (en) 2018-11-01
AU2017247008B2 true AU2017247008B2 (en) 2022-04-07

Family

ID=60000544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017247008A Ceased AU2017247008B2 (en) 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics

Country Status (6)

Country Link
US (1) US11559510B2 (https=)
EP (2) EP4005567A1 (https=)
JP (1) JP2019513828A (https=)
AU (1) AU2017247008B2 (https=)
CA (1) CA3058503A1 (https=)
WO (1) WO2017173498A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173497A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Targeted drug delivery
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
BR112021026559A2 (pt) * 2019-07-17 2022-02-15 Noxopharm Ltd Terapia imuno-oncológica usando compostos isoflavona
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003229A1 (en) * 2007-06-29 2009-01-08 Novogen Research Pty Ltd 2-substituted isoflavonoid compounds, medicaments and uses

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676314B2 (ja) * 1985-09-30 1994-09-28 花王株式会社 坐剤基剤及び坐剤
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20090233999A1 (en) 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
EP1545206B1 (en) * 2002-07-24 2020-03-04 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
JP2007505914A (ja) 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
CA2542351A1 (en) 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
US20050154452A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
EP1794141B1 (en) 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
EP2436680B1 (en) 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
EP1861402B1 (en) 2005-03-24 2011-01-26 Novogen Research Pty. Ltd. Isoflavonoid dimers
EP1948103A2 (en) 2005-09-15 2008-07-30 UMD, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
AU2007314141A1 (en) * 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CA2738328A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
CA2743661C (en) 2008-11-14 2017-01-03 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) * 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
WO2014160130A1 (en) 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US20150126597A1 (en) 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
WO2015117202A1 (en) 2014-02-07 2015-08-13 Novogen Limited Functionalised benzopyran compounds and use thereof
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA3254279A1 (en) * 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
SI3334431T1 (sl) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN109475522A (zh) 2016-04-06 2019-03-15 讷克斯药物有限公司 改善癌症治疗
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CA3058505A1 (en) * 2016-04-22 2017-10-26 Noxopharm Limited Chemotherapy comprising the combination of idronoxil with a sub-therapeutic dose of a taxane or platin
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003229A1 (en) * 2007-06-29 2009-01-08 Novogen Research Pty Ltd 2-substituted isoflavonoid compounds, medicaments and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Noxopharm Limited: ClinicalTrials.gov archive [online], NCT02941523 as on 20 October 2016, URL: https://clinicaltrials.gov/archive/NCT02941523/2016_10_20 *
Royal North Shore Hospital, ClinicalTrials.gov archive [online], NCT03041285 as on 1 February 2017, URL: https://clinicaltrials.gov/archive/NCT03041285/2017_02_01 *

Also Published As

Publication number Publication date
EP3439644A1 (en) 2019-02-13
JP2019513828A (ja) 2019-05-30
US20190117618A1 (en) 2019-04-25
WO2017173498A1 (en) 2017-10-12
AU2017247008A1 (en) 2018-11-01
EP3439644A4 (en) 2019-10-30
EP3439644B1 (en) 2022-01-12
CA3058503A1 (en) 2017-10-12
EP4005567A1 (en) 2022-06-01
US11559510B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
AU2017247008B2 (en) Isoflavonoid composition with improved pharmacokinetics
US20260027079A1 (en) Cannabinoid acid ester compositions and uses thereof
AU2021266308B2 (en) Chemotherapy improvements
RU2508116C2 (ru) Способ и композиции для лечения рака
CN112654626A (zh) 化合物及其用途
AU2020204172A1 (en) Improvements in cancer treatment
TWI834868B (zh) 難治性癌症之預防或治療用之醫藥組合物
CA3017552A1 (en) Combination therapy for proliferative diseases
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
WO2025093572A1 (en) Solid dispersion compositions and uses thereof
HK40006250A (en) Improvements in cancer treatment
Croasdell Digestive Disease Week 2017. Chicago, Illinois, USA-May 6-9, 2017
CN101610771A (zh) 肝癌治疗剂
HK1178458A (en) Therapeutic agent for liver cancer
HK1138797A (zh) 肝癌治疗剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired